Sanofi’s Rilzabrutinib Gains Orphan Drug Status for Sickle Cell Disease

The latest announcement is out from Sanofi ( (SNY) ).

In June 2025, Sanofi announced that the FDA granted orphan drug designation to rilzabrutinib for sickle cell disease, marking its fourth such designation for the drug in rare diseases. This designation highlights Sanofi’s commitment to addressing unmet medical needs in rare diseases, with rilzabrutinib currently under regulatory review in multiple regions for immune thrombocytopenia. Additionally, Sanofi introduced its 2025 Global Employee Stock Purchase Plan, reflecting its ongoing efforts to engage and invest in its workforce.

The most recent analyst rating on (SNY) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.

Spark’s Take on SNY Stock

According to Spark, TipRanks’ AI Analyst, SNY is a Neutral.

Sanofi’s overall stock score reflects strong earnings performance and a stable financial foundation, despite technical challenges and valuation concerns. The earnings call was particularly impactful, highlighting strategic growth areas and effective management. Technical indicators suggest a cautious approach, while the valuation is slightly stretched.

To see Spark’s full report on SNY stock, click here.

More about Sanofi

Sanofi is an R&D driven, AI-powered biopharma company dedicated to improving lives and fostering growth through innovative medicines and vaccines. The company leverages its deep understanding of the immune system to address urgent healthcare challenges, with a focus on rare diseases and immune-mediated conditions. Sanofi is listed on EURONEXT and NASDAQ.

Average Trading Volume: 2,812,289

Technical Sentiment Signal: Buy

Current Market Cap: $121.6B

See more data about SNY stock on TipRanks’ Stock Analysis page.